In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.

Liquidia's collaboration with Sandoz and development of new products like L606 show promise. Learn why LQDA stock is a Hold.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

StockNews.com assumed coverage on shares of Tenax Therapeutics (NASDAQ:TENX – Free Report) in a research report report published on Sunday morning. The brokerage issued a sell rating on the specialty ...

United Therapeutics (UTHR) announced that ten posters and presentations across its commercial and development portfolio will be presented at ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

Learn more about whether Jazz Pharmaceuticals plc or Johnson & Johnson is a better investment based on AAII's A+ Investor ...

CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk ...

The FDA is poised to issue a final decision on the approval and marketing of Yutrepia, an inhaled dry powder formulation of ...

The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...

Korea Investment CORP grew its stake in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 6.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 39,289 shares ...

The company's current focus spans the development and commercialization of products in pulmonary hypertension and other ... the timelines or outcomes related to patent litigation with United ...